跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
联系专家
查看 Scopus 资料
Toguri James Thomas
Professor
Dalhousie University
,
Chemistry
电子邮件
TJ437900
dal
ca
网站
https://www.scopus.com/authid/detail.url?authorId=56035437900
h-index
h10-index
h5-index
451
引用
12
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
371
引用
12
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
42
引用
3
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
2013
2020
每年的科研成果
综述
指纹
网络
科研成果
(19)
相似简介
(6)
指纹
深入其中 Toguri James Thomas 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
分类
加权
按字母排序
Keyphrases
Immune Cell Activity
83%
CB 2
83%
Blood Vessels
83%
Colloids
83%
Advanced Cancer Patients
83%
Endotoxin-induced Uveitis
83%
Convolutional Neural Network
83%
Thermostat
83%
Over-the-horizon
83%
Intravitreal Bevacizumab
83%
Allosteric Interactions
83%
Student Exposure
83%
Inflammatory Targets
83%
Career Interest
83%
Murine Retina
83%
Inflammation
83%
Activator protein-1 (AP-1)
50%
Intravitreal Antibiotics
41%
ON-bipolar Cells
41%
Nepafenac
33%
CB1R Antagonist
23%
WAY-100635
23%
Intraocular Injection
20%
Reporter Mice
20%
Light Adaptation
20%
Immunohistochemical Study
20%
Lipidomics
20%
Histopathological Index
20%
Bevacizumab Treatment
20%
Alpha Wave
20%
Extraocular
20%
Retinal Signaling
20%
CB2 Antagonist
20%
Healthy Retina
20%
Neuronal Expression
20%
In Vivo Methods
20%
Promising Drug
16%
CB2 Receptor Agonist
16%
Topical Treatment
16%
CCL5
16%
Mediator Release
16%
Ocular Anti-inflammatory
16%
Uveitis
16%
Ciliary Body
16%
Ocular Ischemic Syndrome
16%
Neutrophil Migration
13%
N-oleoyl Glycine
13%
Lipoate
13%
Dispase
13%
Iris Microvasculature
13%
Medicine and Dentistry
Leukocyte
95%
Eye Inflammation
83%
Bevacizumab
83%
Microcirculation
83%
Lipidome
83%
Nabiximols
83%
Infection
83%
Endotoxin-Induced Uveitis
75%
Chemokine
56%
Microvessel
53%
Serositis
53%
Peptidoglycan
47%
Lipopolysaccharide
47%
Cytokine
44%
Leukocyte Recruitment
41%
Eye Disease
41%
Vasculotropin
35%
Intravital Microscopy
32%
Vitrectomy
23%
Iris
23%
RANTES
23%
Irritant Agent
23%
Endophthalmitis
23%
Interleukin-6
23%
Interleukin-1
23%
Antibiotics
23%
Tumor Necrosis Factor
23%
T-Cell Response
20%
T Cell
20%
Immune Response
20%
Early Intervention
20%
Serotonin 1A Antagonist
20%
N [2 [4 (2 Methoxyphenyl) 1 Piperazinyl]ethyl] N (2 Pyridyl)cyclohexanecarboxamide
20%
Ex Vivo
20%
Ethanolamine
16%
Anti-Inflammatory Drug
11%
Leukocyte Adherence
11%
Vascular Endothelium
11%
Antiinflammatory Activity
11%
Eye Surgery
11%
Immunoglobulin G1 Antibody
11%
Antiinflammatory Agent
11%
Interleukin 13
11%
Eotaxin
11%
Inflammatory Cytokine
11%
Granulocyte Macrophage Colony Stimulating Factor
11%
Enucleation
11%
Adjuvant Therapy
11%
Visual Impairment
11%
Granulocyte Colony Stimulating Factor
11%
Neuroscience
Cannabinoid
100%
Lipidome
83%
Uveitis
83%
Endocannabinoid System
83%
Antipsychotic
83%
Ophthalmic Disorder
83%
Nabiximols
83%
Haloperidol
37%
Prednisolone
27%
Nepafenac
27%
Adaptive Response
27%
Globus pallidus
27%
Olanzapine
27%
Typical Antipsychotic
27%
Neutrophil Granulocyte
22%
5-HT1A Receptor
20%
Eicosanoid Receptor
18%
Cannabis
16%
Intraocular Pressure
16%
Glaucoma
16%
Lipid Signaling
15%
Anti-Inflammatory Agent
13%
Iris
13%
CXCL2
13%
CB2 Receptor Agonist
13%
CCL5
13%
Chemokine
13%
Ciliary Body
13%
Corneal Epithelium
10%
5-HT1A Antagonists
10%
Cannabinoid Receptor
9%
Receptor Agonists
9%
Atypical Antipsychotic
9%
Gamma-Aminobutyric Acid
9%
Cell Culture
9%
Cannabinoid Receptor Type 1
9%
Neural Circuit
9%
Medium Spiny Neuron
9%
Choroid
7%
Uvea
7%
